Back to Journals » International Journal of Nanomedicine » Volume 7

A silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1

Authors Qu, Li, Hovgaard L, Li, Dai W, Wang J, Zhang X , Zhang Q

Received 17 January 2012

Accepted for publication 12 March 2012

Published 14 September 2012 Volume 2012:7 Pages 4983—4994


Review by Single anonymous peer review

Peer reviewer comments 3

Wei Qu,1,2 Yong Li,2,* Lars Hovgaard,3 Song Li,1 Wenbin Dai,1 Jiancheng Wang,1 Xuan Zhang,1 Qiang Zhang1,*

1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, PR China; 2Department of Nutrition and Food Hygiene, Peking University Health Science Center, Beijing 100191, PR China; 3Oral Formulation Development, Novo Nordisk A/S, Maalov, Denmark

*Both authors contributed equally to this work

Background: Glucagon-like peptide-1 (GLP-1) (7–36) is a peptide incretin hormone released from the endocrine L-cells of the intestinal mucosa with unique antidiabetic potential. Due to low absorption efficiency and instability in the gastrointestinal tract, the introduction of orally active GLP-1 is a large challenge. Here we developed a novel silica-based pH-sensitive nanomatrix of GLP-1 (SPN-GLP-1) in order to provide a strategy for oral peptide delivery.
Methods: SPN-GLP-1 composed of silica nanoparticles and pH-sensitive Eudragit® was prepared and characterized by dynamic light scattering, scanning electron microscope, transmission electron microscope, high-performance liquid chromatography, surface analysis, drug release, and so on. Its permeability across the Caco-2 cell monolayer and intestinal mucosa, proteolytic stability against the intestinal enzymes, pharmacokinetics, hypoglycemic effect in the intraperitoneal glucose tolerance test (IPGTT), and primary toxicity were then evaluated.
Results: It was indicated that the nanomatrix system obtained had a unique nanoscale structure and pH-sensitivity in drug release. It displayed a five-fold intestinal mucosa permeability and significantly higher proteolytic stability compared to native GLP-1 (P < 0.001). A longer half-life was observed after oral administration of SPN-GLP-1, and its relative bioavailability was 35.67% in comparison to intraperitoneal GLP-1. Oral delivery of SPN-GLP-1 significantly reduced the blood glucose level and its hypoglycemic effect over intraperitoneal GLP-1 reached 77%. There was no evident toxicity of SPN-GLP-1 found from both animal status and histochemical analysis of gastrointestinal tissues.
Conclusion: The silica-based pH-sensitive nanomatrix designed and prepared here might be considered as a potential oral delivery system not only for GLP-1, but also for other peptide or macromolecular drugs.

Keywords: nanomatrix, oral peptide delivery, silicon nanoparticles, pH-sensitive, GLP-1

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.